GSK gains FDA Fast Track designation for chronic hepatitis B treatment

Betsy Goodfellow | February 12, 2024 | News story | Medical Communications |  FDA, GSK, Hepatology, fast track designation, hepatitis B 

GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB).

The designation was requested as the drug has a potential to address an unmet medical need for CHB, and follows data from the phase 2b trials B-Clear and B-Sure, both of which assessed the efficacy, safety and durability of the response of the drug in patients with CHB. The confirmatory phase 3 programme, B-Well, is currently taking place.

According to the company’s press release: ‘Bepirovirsen is the only single agent in phase 3 development that has shown the potential to achieve clinically meaningful functional cure response when combined with oral nucleoside/nucleotide analogues (NAs). This was demonstrated by positive results in the B-Clear and B-Sure clinical trials. B-Clear identified that patients with low baseline hepatitis B surface antigen levels are most likely to benefit from treatment with bepirovirsen. Bepirovirsen is also being investigated as a potential backbone therapy in future sequential regimens to pursue functional cure in a broader population of patients with CHB’.

Advertisement

Betsy Goodfellow

Related Content

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

The Gateway to Local Adoption Series

Latest content